Kamada Ltd. (KMDA)
NASDAQ: KMDA · Real-Time Price · USD
8.34
+0.27 (3.35%)
At close: Mar 31, 2026, 4:00 PM EDT
8.38
+0.04 (0.48%)
Pre-market: Apr 1, 2026, 4:03 AM EDT
Kamada Revenue
In the year 2025, Kamada had annual revenue of $180.46M with 12.12% growth. Kamada had revenue of $44.68M in the quarter ending December 31, 2025, with 14.54% growth.
Revenue (ttm)
$180.46M
Revenue Growth
+12.12%
P/S Ratio
2.63
Revenue / Employee
$390,606
Employees
462
Market Cap
475.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 180.46M | 19.51M | 12.12% |
| Dec 31, 2024 | 160.95M | 18.43M | 12.93% |
| Dec 31, 2023 | 142.52M | 13.18M | 10.19% |
| Dec 31, 2022 | 129.34M | 25.70M | 24.79% |
| Dec 31, 2021 | 103.64M | -29.60M | -22.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 837.32M |
| Emergent BioSolutions | 742.90M |
| Organogenesis Holdings | 564.17M |
| Esperion Therapeutics | 403.14M |
| Ironwood Pharmaceuticals | 296.15M |
| Akebia Therapeutics | 236.20M |
| Canopy Growth | 203.04M |
| SIGA Technologies | 94.57M |
KMDA News
- 6 days ago - Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas - GlobeNewsWire
- 20 days ago - Kamada Ltd (KMDA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook - GuruFocus
- 20 days ago - Q4 2025 Kamada Ltd Earnings Call Transcript - GuruFocus
- 20 days ago - Kamada Ltd. (KMDA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Kamada (KMDA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Nasdaq
- 20 days ago - Kamada Shares Slip Despite Record FY25 Results And Dividend Declaration - Nasdaq
- 21 days ago - Earnings Scheduled For March 11, 2026 - Benzinga
- 21 days ago - Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth - GlobeNewsWire